The UK and US have secured a major commercial pact that will guarantee no levies on British medicine products going into the American market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to boost funding on medicines through the NHS. This pledge guarantees that duties on these crucial exports will be held at nothing for a duration of the next three years.
This agreement follows earlier warnings to dramatically increase import taxes on patented pharmaceutical products, with increases discussed reaching 100%.
"This deal with the Britain strengthens the international landscape for new treatments and introduces long-overdue balance to American-British medicine commerce," an announcement declared.
Trade Significance
Drugs are one of the UK's biggest goods shipped to the US, which is clearly the largest destination for major companies like GSK and AstraZeneca.
Trade data show that in the 12 months prior to September, the UK exported medicines totaling billions to the US. This amount accounted for 17.4% of British export trade in that timeframe.
"This guarantee safeguards jobs, stimulates capital expenditure and paves the way for the UK to establish itself as a worldwide center for medical research," a minister remarked.
Specific British Pledges
The deal involves several notable changes from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new treatments to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to double total health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The amount drug companies must return to the NHS to prevent overspending will be restricted at 15%. In the past, rebates exceeded 20%.
Industry Background
The deal follows a protracted dispute between the pharmaceutical industry and the ministers over drug pricing and NHS adoption.
The disagreement were exacerbated by arguments that American patients were charged a premium for the identical medicines than patients in the Britain and the EU.
In recent months, several large drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been pledged toward US facilities.
The Science Minister stated that the NHS must spend more on medicines, noting that its spending on drugs had shrunk as a proportion of its total funding over the previous ten-year period.
